1530 On Other Exchanges
1530 is not on other exchanges.

3sbio inc (1530) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for 3SBIO INC (1530)

3sbio inc (1530) Related Bloomberg News

View More Bloomberg News

3sbio inc (1530) Related Businessweek News

No Related Businessweek News Found

3sbio inc (1530) Details

3SBio Inc. develops, manufactures, markets, and sells biopharmaceuticals. Its products include TPIAO, a recombinant human thrombopoietin for thrombocytopenia; and EPIAO, an injectable recombinant human erythropoietin for anemia associated with chronic kidney disease (CKD) and chemotherapy, as well as to reduce allogeneic blood transfusion in surgery patients. The company also offers IV Iron Sucrose, an iron sucrose injection product for iron deficiency anemia; SEPO, an injectable product for anemia associated with CKD, as well as CIA; and Sparin, an injectable low-molecular-weight heparin calcium product for prophylaxis and vein thrombosis, and to prevent clotting during hemodialysis. In addition, it provides Intefen, a recombinant human interferon alpha-2a product for the treatment of malignancies of the lymphatic or hematopoietic system, and viral infectious diseases; and Inleusin, a recombinant human interleukin 2 product for renal cell carcinoma, melanoma, thoracic fluid build-up caused by cancer, and tuberculosis; and Gan Xin, a metadoxine drug for alcoholic liver disease. Further, the company offers Qiming Keli for Type 2 diabetic retinopathy; Yi Li Xi, a TZDS antidiabetic drug; Man di, an OTC drug for baldness; Lai Zi, a tacrolimus ointment for atopic dermatitis; Di Su, a BCG-PSN injection for chronic bronchitis, cold, and asthma; Lai Duo Fei for allergic rhinitis and antihistamines; Liranaftate, a glucosinolates carbamate antifungal drug for the treatment of tinea pedis, tinea corporis, and tinea cruris; and Amikacin to treat trauma infection caused by bacteria, as well as distributes anti-cancer drugs, such as Docetaxel, Anastrozole, and Azasetron. 3SBio Inc. sells its products to hospitals and medical institutions through in-house sales and marketing team, distributors, and third-party promoters. The company was incorporated in 2006 and is headquartered in Shenyang, the People’s Republic of China. 3SBio Inc. is a subsidiary of Decade Sunshine Limited.

2,177 Employees
Last Reported Date: 04/28/16
Founded in 2006

3sbio inc (1530) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: CNY432.0K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: CNY460.0K
Senior Vice President and Executive Director
Total Annual Compensation: CNY497.0K
Vice President and Executive Director
Total Annual Compensation: CNY476.0K
Compensation as of Fiscal Year 2015.
3sbio inc
Zhenping Zhu Joins 3SBio Inc. as President of Research & Development and Chief Scientific Officer

3SBio Inc. announced that Zhenping Zhu, MD, PhD, has joined 3SBio as its new President of Research & Development and Chief Scientific Officer. Dr. Zhu has extensive research and development experience within the biotechnology industry. Prior to joining 3SBio, He served as Executive Vice President, Global Biopharmaceuticals, Kadmon Corporation, and President of Kadmon China.

3SBio Inc. Presents at UBS Greater China Conference 2017, Jan-09-2017

3SBio Inc. Presents at UBS Greater China Conference 2017, Jan-09-2017 . Venue: China Hall, 3/F, Grand Tower, Shangri-La Shanghai Pudong, Shanghai 738, China.

3SBio Inc. Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2016

3SBio Inc. reported unaudited consolidated earnings results for the six months ended June 30, 2016. For the six months ended 30 June 2016, the group's revenue was RMB 1,304.9 million, as compared to RMB 790.3 million for the six months ended 30 June 2015, representing an increase of approximately RMB 514.5 million, or 65.1%. The increase is mainly attributable to the sales growth of the group's key products and the consolidation of the revenues of Zhejiang Wansheng and Guojian into the Group's financial information since 1 August 2015 and 1 April 2016, respectively. The group's normalized EBITDA increased by RMB 181.9 million or 48.8% to RMB 554.9 million, as compared to the six months ended 30 June 2015. Normalized net profit increased by RMB 56.7 million or 19.0% to RMB 354.8 million as compared to the six months ended 30 June 2015. Profit before tax was RMB 352.595 million against RMB 278.302 million a year ago. Profit attributable to owners of the parent as RMB 286.852 million or RMB 0.11 diluted per share against RMB 242.496 million or RMB 0.12 diluted per share a year ago. Net cash flows from operating activities was RMB 394.837 million against RMB 267.190 million and purchase of items of property, plant and equipment was RMB 38.559 million against RMB 20.103 million for the last year.


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

1530 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 1530.
View Industry Companies

Industry Analysis


Industry Average

Valuation 1530 Industry Range
Price/Earnings 100.0x
Price/Sales 162.2x
Price/Book 48.2x
Price/Cash Flow 4.8x
TEV/Sales 0.1x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact 3SBIO INC, please visit www.3sbio.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.